secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001558370-25-002599
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M
--------------------------------------------------------------------------------

- FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.
- Q4 2024 product sales $7.9M (+13% QoQ); EBITDA loss $0.6M; cash $26.6M at Dec 31, 2024.
- Early repaid $13M of ~$32M convertible debt, saving ~$1.5M annual interest; reduces potential dilution.
- Full-year operating income $2.6M vs loss $12.8M in 2023; G&A declined QoQ after one-time CEO severance.
- PEDMARQSI launched in UK and Germany; Japan trial results (STS-J01) expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/0001558370-25-002599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer